Status:
COMPLETED
Biomarkers to Predict the Response to Pembrolizumab in Chinese NSCLC Patients
Lead Sponsor:
Kiang Wu Hospital
Conditions:
NSCLC Stage IV
Eligibility:
All Genders
18-80 years
Brief Summary
Pembrolizumab is approved for advanced stage non-small cell lung cancer. However, the response rate is low (around 10-15 %) in patients treated in Macau SAR, China. The investigators hypothesize CD38 ...
Detailed Description
Lung cancer is the leading cause of cancer death, the overall survival rate is low. Recently, using anti-PD-L1 immunotherapy for treatment of cancer shows promising in some types of cancer, including ...
Eligibility Criteria
Inclusion
- Above 18 years of age
- Locally advanced (stage IIIB) or metastatic (stage IV) NSCLC, not amenable to curative surgery or radiotherapy
- With PD-L1test available
- Progressed on previous treatment, or treatment native patients. Patients may have also received additional lines of treatment
- Received pembrolizumab treatment in the participating site.
Exclusion
- Enrollment in studies that prohibit any participation in this observational study
- No serum samples available
Key Trial Info
Start Date :
January 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 1 2020
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT04076228
Start Date
January 1 2017
End Date
January 1 2020
Last Update
September 2 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kiang Wu Hospital
Macao, China, 999078